Microenvironment effects on promoting upregulation of matrix metalloproteinases in Bcl-2-overexpressing renal cell carcinoma as a response to doxorubicin treatment inducing the production of metastasis

Tumor Biology

Volumn 28, Issue 3, 2007, Pages 181-188

  Ahn, Kwang Sung ^a,b   Bae, Eunkyung ^a   Jeon, Seong Soo ^a   Yoon, Sung Soo ^b   Lee, Young Yuil ^c   Choi, Han Yong ^a,d  

^a Samsung Medical Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antiapoptosis; Bcl 2; Chemoresistance; Distant metastasis; Human renal cell carcinoma

Indexed keywords

CASPASE 3; DOXORUBICIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PROTEIN BAX; PROTEIN BCL 2;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROTECTION; CONTROLLED STUDY; DIMERIZATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 34250791491     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103381     Document Type: Article

References (23)

1. Amato RJ: Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-186.
2. Townson JL, Naumov GN, Chambers AF: The role of apoptosis in tumor progression and metastasis. Curr Mol Med 2003;3:631-642.
3. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326.
4. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, Bastianutto C, Liu FF: Combination Bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 2005;11:8131-8144.
5. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME: A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005;4:1689-1698.
6. Kelly JD, Dai J, Eschwege P, Goldberg JS, Duggan BP, Williamson KE, Bander NH, Nanus DM: Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas. Br J Cancer 2004;91:164-170.
7. Kausch I, Jiang H, Thode B, Doehn C, Kruger S, Jocham D: Inhibition of Bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Eur Urol 2005;47:703-709.
8. Ilmonen S, Hernberg M, Pyrhonen S, Tarkkanen J, Asko-Seljavaara S: Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res 2005;15:375-381.
9. Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M: Bcl-2 over-expression enhances NF-κB activity and induces MMP-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer 2000;86:188-196.
10. 2+/calmodulin-dependent protein kinase IV. J Cell Biochem 2005;95:1214-1223.
11. Skolarikos A, Alivizatos G, Bamias A, Mitropoulos D, Ferakis N, Deliveliotis C, Dimopoulos MA: Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis? Int J Urol 2005;12:563-569.
12. Fernandez Y, Gu B, Martinez A, Torregrosa A, Sierra A: Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int J Cancer 2002;101:317-326.
13. Yoon SS, Ahn KS, Kim SH, Kim JK: In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype. Lung Cancer 2001;33:221-228.
14. Ahn KS, Jung YS, Kim J, Lee H, Yoon SS: Behavior of murine renal carcinoma cells grown in ectopic or orthotopic sites in syngeneic mice. Tumor Biol 2001;22:146-153.
15. Fidler IJ: Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 2001;10:257-269, vii-viiii.
16. Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 2002;70:498-505.
17. Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995;87:1588-1592.
18. Killion JJ, Radinsky R, Fidler IJ: Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-284.
19. McConkey DJ, Greene G, Pettaway CA: Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56:5594-5599.
20. Murata T, Haisa M, Uetsuka H, Nobuhisa T, Ookawa T, Tabuchi Y, Shirakawa Y, Yamatsuji T, Matsuoka J, Nishiyama M, Tanaka N, Naomoto Y: Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. Int J Mol Med 2004;13:865-868.
21. Staroselsky AN, Mahlin T, Savion N, Klein O, Nordenberg J, Donin N, Michowitz M, Leibovici J: Metastatic potential and multidrug resistance correlation in the B16 melanoma system. J Exp Ther Oncol 1996;1:251-259.
22. Trisciuoglio D, Desideri M, Ciuffreda L, Mottolese M, Ribatti D, Vacca A, Del Rosso M, Marcocci L, Zupi G, Del Bufalo D: Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005;205:414-421.
23. Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M: BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett 1998;440:419-424.